Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCSO-524 is a patented, stabilized lipid extract derived from the New Zealand green-lipped mussel (Perna canaliculus). It is primarily used as a natural anti-inflammatory supplement in veterinary medicine and as a dietary supplement for humans. The formulation contains a complex blend of over 90 free fatty acids, including omega-3 polyunsaturated fatty acids such as EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid), and ETA (eicosatetraenoic acid). Its mechanism of action involves inhibition of pro-inflammatory mediators, notably leukotriene B4 and prostaglandin E2 biosynthesis, as well as moderate inhibition of cyclooxygenase enzymes COX‑1 and COX‑2. This results in reduced production of inflammatory cytokines like TNF‑α and IFN‑γ. PCSO‑524 has demonstrated efficacy in reducing symptoms associated with osteoarthritis, atopic dermatitis, asthma, exercise-induced muscle soreness, and airway inflammation in both animal models and clinical studies[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PCSO-524.